1. Bouzaiene Boussen H,Dhiab Ben Hassouna J,Benna Khomsi F,clinical .Cancer (2010). Inflammatory breast cancer in Tunisia: epidemiological and clinical trends.
2. Mourali N,Muenz LR,Tabbane F,Belhassen S,Bahi J (1980). Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer, 46(12), 27412746.
3. Shine Chang,Sheryl Parker,Tuan Pham,Aman Buzdar,Stephen Hursting (1998). Inflammatory breast carcinoma incidence and survival. Cancer, 82(12), 2366-2372.
4. Hance KW,Anderson WF,Devesa SS,Young HA,Levine PH (2005). Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst. 2005 Jul 6, 97(13), 966-975.
5. Glenn Lawson JS,Ye Salmons B,Moody Heng B (2010). Mouse Mammary Tumor Virus–like Sequences in Human Breast Cancer. 2010 May 1, 70(9), 3576-3585.
6. S. Singletary,Massimo Cristofanilli (2008). Defining the Clinical Diagnosis of Inflammatory Breast Cancer seminars in oncology. Seminars in Oncology, 35(1), 7-10.
7. William Anderson,Catherine Schairer,Bingshu Chen,Kenneth Hance,Paul Levine (2005). Anderson, Catherine Schairer, Bingshu E Chen, Kenneth W Hance, Paul H Levine Epidemiology of inflammatory breast cancer Breast Disease Breast Dis. Breast Disease, 22, 9-23.
8. (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 22(3), 515-523.
9. Paradiso A,Tommasi S,Brandi M,Marzullo F,Simone G (1989). Cell kinetics and hormonal receptor status in inflammatory breast carcinoma: Comparison with locally advanced disease Cancer. Cancer, 64(9)
10. William Anderson,Kenneth Chu,Shine Chang (2003). Inflammatory Breast Carcinoma and Noninflammatory Locally Advanced Breast Carcinoma: Distinct Clinicopathologic Entities?. Journal of Clinical Oncology, 21(12), 2254-2259.
11. (2008). Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry. BMC Cancer, 8, 28.
12. Chaher N,Arias-Pulido H,Terki N,Qualls C,Bouzid K,Verschraegen C (2012). Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients Breast Cancer Res Treat. 2012 Jan, 131(2), 437-444.
13. Gabillot Guerin M,JP MC Mathieu,N. M Spielmann (1989). Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance International Journal of Cancer Volume 43. International Journal of Cancer, 43(2), 201-208.
14. (2004). p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer. Clinical Cancer Res, 10, 6215.
15. Kleer CG,Van KL,Braun T,Merajver SD (2001). Persistent E-Cadherin Expression in Inflammatory Breast Cancer. Modern Pathoogy, 14(5), 458-464.
16. PB CG Colpaert,A. I Benoy,F. Van Roy (2003). Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression British Journal of Cancer 2003. British Journal of Cancer, 88(5), 718-725.
17. L. Kenneth,Seena van Golen,Davies,Fen Zhi,Yunfang Wu,Corazon Wang (1999). van Golen, Seena Davies, Zhi Fen Wu, YunFang Wang, Corazon D Bucana, Holly Root, : A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory Breast cancer), and Rhoc GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res, 5(9), 2511-2519.
18. Yamauchi H,Woodward WA,Valero V,Alvarez RH,Lucci A,Buchholz TA Inflammatory Breast Cancer: What We Know and What We Need to Learn. The Oncologist, 17(7), 891-899.
19. T. Naoto,Aman Ueno,Sonja Buzdar,Frederick Singletary,Marsha Ames,McNeese (1997). Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemotherapy and Pharmacology, 40(4), 321-329.
20. Massimo Cristofanilli,Ana Gonzalez-Angulo,Aman Buzdar,Shu-Wan Kau,Debbie Frye,Gabriel Hortobagyi (2004). Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M D Anderson Cancer Center experience Clin Breast Cancer. Clinical Breast Cancer, 4(6), 415-419.
21. Eiermann Gianni L,Manikhas Semiglazov V,Lluch A,locally cancer,The trial (2010). Lancet. The Lancet, 375(9712), 377-384.
22. Bernard Chevallier,Bernard Asselain,Antoine Kunlin,Corinne Veyret,Philippe Bastit,Yvon Graic (1987). Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer, 60(4), 897-902.
23. I. Faneyte,J. Schrama,J. Peterse,P. Remijnse,S. Rodenhuis,M. van de Vijver (2003). Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ.Breast cancer response to neoadjuvant chemotherapy : predictive markers and relation with outcome. Cancer, 88, 406-412.
24. J. Eur (1992). E Belembaogo, V Feillel, P Chollet, H Cure, P Verrelle, F Kwiatkowski, Neoadjuvant chemotherapy in 126 operable breast cancers. Cancer 1992; 28A, 896-900.
25. Ames Smith TL,Dhingra Hunt KK (1999). Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. J Clin Oncol, 17, 460-469.
26. Robertson FM,Bondy M,Yang W,Yamauchi H,Wiggins S,Kamrudin S (2010). Inflammatory breast cancer: the disease, the biology, the treatment, CA Cancer J Clin. 2010 Nov-Dec, 60(6), 351-375.
27. C. Colpaert,P. Vermeulen,L. Dirix,Van Marck,E. (2003). Microvessel density, expression of oestrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast Cancer Clin Cancer Res. Clin Cancer Res, 9(10 Pt 1), 3815-3816.
28. Pierga JY,Petit T,Delozier T,Ferrero JM,Campone M,Gligorov J (2012). Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study Lancet Oncol. 2012 Apr, 13(4), 375-384.
29. S. Rabiya,Tuma (2012). ALK gene amplified in most inflammatory breast cancers. JNCI J Natl Cancer Inst, 104(2), 87-88.